AI generated
Jul 18, 2026, 13:42
Chokri Ben Lamine: Optimizing PBSC Donation in Hemoglobinopathy Carriers
Chokri Ben Lamine, Assistant Consultant at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Sickle Cell Trait (HbAS) plus Alpha-Thalassemia Trait in a Stem Cell Donor: Key Precautions
Before donor clearance.
Confirm genotype:
- Hb electrophoresis/HPLC (HbAS)
- α-globin gene testing if α-thalassemia suspected
- CBC, reticulocyte count, ferritin
- Renal and liver function
- Ensure no underlying anemia requiring investigation
Is donation contraindicated?
No. HbAS and α-thalassemia trait alone are not contraindications to peripheral blood stem cell (PBSC) donation if the donor is otherwise healthy.
Individual assessment remains essential.
G-CSF mobilization
Standard filgrastim (G-CSF) dosing:
- 10 µg/kg/day SC for 4–5 days
- Monitor symptoms closely.
Potential concerns in HbAS donors
- Bone pain (common)
- Rare vaso-occlusive–like complications reported
- Splenic enlargement (rare splenic rupture)
- Dehydration may increase sickling risk
- Monitor oxygenation if symptomatic
Risk reduction
- Maintain excellent hydration before, during, and after mobilization.
- Avoid dehydration, extreme exercise, high altitude, and hypoxia.
- Promptly evaluate chest pain, dyspnea, severe bone pain, abdominal pain, or neurologic symptoms.
During mobilization
- Daily symptom assessment
- CBC before collection
- Consider chemistry panel if clinically indicated
- Stop evaluation if severe toxicity develops
Apheresis. Generally safe.
Watch for:
- Citrate-induced hypocalcemia
- Vasovagal reactions
- Adequate hydration throughout collection
Alpha-thalassemia trait
- Usually does not affect donor eligibility.
- Mild microcytosis alone is not iron deficiency.
- Avoid empiric iron unless deficiency is documented.
Recipient considerations
- HbAS donor grafts have demonstrated successful engraftment.
- Inform the transplant team of donor hemoglobinopathy status for documentation and long-term follow-up.
Bottom line
- HbAS ± α-thalassemia trait is generally acceptable for PBSC donation after careful donor evaluation.
- Hydration, avoidance of hypoxia, and close monitoring during G-CSF mobilization and apheresis are the key precautions.
References
- WBMT Consensus Recommendations
- FACT–JACIE International Standards for Hematopoietic Cellular Therapy
- EBMT Handbook (2024 edition).”
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH
-
Sep 3, 2026, 03:42Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera
-
Sep 3, 2026, 03:28Katrina Snow: Learning More About Sickle Cell Disease This September
-
Sep 3, 2026, 01:19Himanshu Aggarwal: 1 mg/kg/d Thalidomide Non-Inferior to Standard Dose in Transfusion-Dependent Thalassemia
-
Sep 3, 2026, 01:03SHOT Urges Safe Component Matching While NHSBT Appeals for Black Donors
-
Sep 3, 2026, 00:52David Wallace: FDA Approves MIMRYLO to Target Iron Regulation and Reduce Phlebotomy Burden